

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person* Geffken Daniel E.  (Last) (First) (Middle) C/O PROMIS NEUROSCIENCES INC., 1920 YONGE STREET, SUITE 200  (Street) TORONTO, A6 M4S 3E2  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/07/2022	3. Issuer Name and Ticker or Trading Symbol PromIS Neurosciences Inc. [PMN]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Financial Officer	5. If Amendment, Date Original Filed(Month/Day/Year)
		6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person	

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	5,852	D	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Option (right to buy)	(2)	02/10/2032	Common Shares	8,333	\$ 10.8 (1)	D	
Option (right to buy)	(3)	04/14/2032	Common Shares	8,333	\$ 10.8 (1)	D	
Warrants (right to buy)	08/09/2017	08/09/2022	Common Shares	1,042	\$ 18 (1)	D	

**Reporting Owners**

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Geffken Daniel E. C/O PROMIS NEUROSCIENCES INC., 1920 YONGE STREET, SUITE 200 TORONTO, A6 M4S 3E2			Chief Financial Officer	

**Signatures**

/s/ Jason L. Langford, Attorney-in-Fact for Daniel E. Geffken	07/07/2022
**Signature of Reporting Person	Date

**Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

- (1) Conversion or exercise price is in Canadian dollars.
- (2) The option agreement provides that 20% of the options vested immediately, with the balance vesting ratably over 36 months. The option was granted on March 1, 2017.
- (3) The option agreement provides that the options become exercisable in twelve equal monthly installments beginning one month after the grant. The option was granted on November 12, 2021.

**Remarks:**

Exhibit List: Exhibit 24 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

